PORTFOLIO NEWS ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications January 25, 2022 Read More » eFFECTOR Therapeutics Provides Pipeline and Business Updates January 24, 2022 Read More » A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future TmodTM CAR T Therapy January 18, 2022 Read More » Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference January 11, 2022 Read More » NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs January 10, 2022 Read More » Tenaya Therapeutics Provides 2022 Business Updates January 10, 2022 Read More » Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline January 10, 2022 Read More » ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones January 10, 2022 Read More » Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts January 10, 2022 Read More » Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team January 6, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications January 25, 2022 Read More »
A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future TmodTM CAR T Therapy January 18, 2022 Read More »
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference January 11, 2022 Read More »
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs January 10, 2022 Read More »
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline January 10, 2022 Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones January 10, 2022 Read More »
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts January 10, 2022 Read More »
Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team January 6, 2022 Read More »
